Showing all 10 results
Lynparza (Olaparib)
$5,156.65Rated 4.80 out of 5
(5 Reviews)
DISEASE INDICATIONS: Breast Cancer, Gynaecological Cancer
MANUFACTURER: AstraZeneca AB
USAGE: Oral
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Therapeutic Goods Administration (TGA)
Medsafe (NZ)
Lynparza, also known by its generic name Olaparib, represents a pivotal breakthrough in the field of oncology, specifically in the treatment of certain types of cancer, by harnessing the power of targeted therapy.
$5,156.65
Odomzo (sonidegib)
$5,335.57Rated 4.80 out of 5
(5 Reviews)
DISEASE INDICATIONS: Skin Cancer
MANUFACTURER: Sun Pharmaceutical Industries Europe B.V.
USAGE: Oral
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Therapeutic Goods Administration (TGA)
Odomzo, also known by its generic name Sonidegib, is a remarkable medication that has ushered in new hope for individuals grappling with the challenges of Advanced Basal Cell Carcinoma (BCC), a type of skin cancer that can be both disfiguring and debilitating.
$5,335.57
Onivyde (irinotecan hydrochloride trihydrate)
$1,010.33Rated 5.00 out of 5
(5 Reviews)
DISEASE INDICATIONS: Pancreatic Cancer
MANUFACTURER: Baxalta Innovations GmbH
USAGE: Intravenous
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Therapeutic Goods Administration (TGA)
Medsafe (NZ)
Onivyde (irinotecan hydrochloride trihydrate) is a potent and specialized anti-cancer medication used in the treatment of certain types of advanced or metastatic cancers. This chemotherapy drug belongs to a class of medications known as topoisomerase I inhibitors and is specifically indicated for patients with metastatic adenocarcinoma of the pancreas after previous therapy has failed.
$1,010.33
Perjeta (Pertuzumab)
$2,491.01Rated 4.80 out of 5
(5 Reviews)
DISEASE INDICATIONS: Breast Cancer
MANUFACTURER: Roche Registration Limited
USAGE: Intravenous
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Therapeutic Goods Administration (TGA)
Medsafe (NZ)
Perjeta, also known by its generic name Pertuzumab, is a monoclonal antibody drug developed by Genentech, a member of the Roche Group. It was approved by the United States Food and Drug Administration (FDA) in 2012, marking a significant milestone in the treatment of HER2-positive breast cancer, a particularly aggressive and fast-growing form of the disease. Perjeta is often used in combination with other medications, most notably Herceptin (Trastuzumab), and chemotherapy agents like docetaxel.
$2,491.01
Portrazza (necitumumab)
$7,535.16Rated 5.00 out of 5
(5 Reviews)
DISEASE INDICATIONS: Lung Cancer
MANUFACTURER: Eli Lilly Nederland B.V.
USAGE: Intravenous
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Portrazza, with its generic name Necitumumab, is a monoclonal antibody developed by Eli Lilly and Company. It received approval from the United States Food and Drug Administration (FDA) in late 2015, marking a significant advancement in the treatment of advanced squamous NSCLC.
$7,535.16
Rubraca (rucaparib)
From $1,647.81Rated 4.80 out of 5
(5 Reviews)
DISEASE INDICATIONS: Gynaecological Cancer
MANUFACTURER: Clovis Oncology, Inc.
USAGE: Oral
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Rubraca is indicated for the treatment of women with advanced ovarian cancer who have received two or more prior lines of chemotherapy and have a deleterious BRCA mutation, as detected by an FDA-approved test.
From $1,647.81
Rydapt (midostaurin)
$14,303.19Rated 4.80 out of 5
(5 Reviews)
DISEASE INDICATIONS: Leukemia
MANUFACTURER: Novartis Europharm Limited
USAGE: Oral
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Therapeutic Goods Administration (TGA)
Medsafe (NZ)
Rydapt is a groundbreaking medication, primarily used in combination with standard chemotherapy for newly diagnosed AML patients who have a specific genetic mutation known as FLT3 mutation.
$14,303.19
Tagrisso (Osimertinib)
$5,571.28Rated 5.00 out of 5
(5 Reviews)
DISEASE INDICATIONS: Lung Cancer
MANUFACTURER: AstraZeneca AB
USAGE: Oral
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Therapeutic Goods Administration (TGA)
Medsafe (NZ)
Tagrisso has been a game-changer, specifically targeting EGFR (epidermal growth factor receptor) mutations, which are prevalent in a subset of NSCLC patients.
$5,571.28
Tecentriq (Atezolizumab)
$6,105.91Rated 4.80 out of 5
(5 Reviews)
DISEASE INDICATIONS: Urothelial Carcinoma, Breast Cancer, Lung Cancer
MANUFACTURER: Roche Registration Limited
USAGE: Intravenous
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA)
Therapeutic Goods Administration (TGA)
Medsafe (NZ)
It belongs to a class of drugs known as immune checkpoint inhibitors and has been approved for the treatment of multiple types of cancer.
$6,105.91
Zejula (niraparib)
From $4,886.66Rated 4.80 out of 5
(5 Reviews)
DISEASE INDICATIONS: Gynaecological Cancer
MANUFACTURER: Tesaro UK Limited
USAGE: Oral
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Therapeutic Goods Administration (TGA)
Zejula is primarily indicated for the treatment of ovarian cancer and, in some cases, breast cancer.
From $4,886.66
